The Food and Drug Administration (FDA) has approved the Guardian Connect continuous glucose monitoring (CGM) system (Medtronic) for patients with diabetes ages 14 to 75 years.
Using an advanced glucose sensor, the Guardian Connect system is able to provide predictive alerts to warn patients of potentially high or low glucose events up to 60 minutes in advance. In a clinical trial, the system was able to accurately alert patients of 98.5% of hypoglycemic events.
The system also allows caregivers to monitor the users glucose levels in real-time.
Users also have access to the Company’s Sugar.IQ app, which uses IBM’s Watson Health platform, to identify glucose patterns based on factors that may affect them (ie, food intake, insulin dosages, daily routines). Used with the Guardian Connect system, the Sugar.IQ app provides actionable insights for the user to reach their target glucose level.
“Greater utilization of smarter CGM systems promises to allow our patients to achieve more glycemic time-in-range and to further reduce the risk of hypoglycemia,” said Dr. Timothy Bailey, director of the AMCR Institute and associate professor at UC, San Diego.
The company says the device will be made available some time between May and July, 2018.
For more information visit Medtronic.com.
This article originally appeared on MPR